AMAG Pharmaceuticals Inc. (AMAG)’s Financial Results Comparing With Kamada Ltd. (NASDAQ:KMDA)

AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) and Kamada Ltd. (NASDAQ:KMDA), are influenced by contrast since they are both players in the Biotechnology. These factors are particularly influence the risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership of the two firms.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AMAG Pharmaceuticals Inc. 12 0.69 N/A -6.77 0.00
Kamada Ltd. 6 1.88 N/A 0.64 8.80

Table 1 highlights AMAG Pharmaceuticals Inc. and Kamada Ltd.’s top-line revenue, earnings per share (EPS) and valuation.


Table 2 represents AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) and Kamada Ltd. (NASDAQ:KMDA)’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
AMAG Pharmaceuticals Inc. 0.00% -18.7% -10.1%
Kamada Ltd. 0.00% 0% 0%

Analyst Recommendations

AMAG Pharmaceuticals Inc. and Kamada Ltd. Ratings and Recommendations are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
AMAG Pharmaceuticals Inc. 0 2 1 2.33
Kamada Ltd. 0 0 1 3.00

AMAG Pharmaceuticals Inc.’s upside potential currently stands at 61.01% and an $14.33 consensus price target.

Insider & Institutional Ownership

Roughly 0% of AMAG Pharmaceuticals Inc. shares are held by institutional investors while 25.39% of Kamada Ltd. are owned by institutional investors. Insiders held roughly 3.5% of AMAG Pharmaceuticals Inc.’s shares. Competitively, Kamada Ltd. has 27.75% of it’s share held by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
AMAG Pharmaceuticals Inc. -5.06% -18.7% -23.73% -46.22% -61.13% -45.62%
Kamada Ltd. -2.07% 2.9% -2.74% 8.41% -0.53% 13.4%

For the past year AMAG Pharmaceuticals Inc. had bearish trend while Kamada Ltd. had bullish trend.


Kamada Ltd. beats AMAG Pharmaceuticals Inc. on 7 of the 9 factors.

AMAG Pharmaceuticals, Inc., a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for womenÂ’s health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units for pregnant women and their families. In addition, it has a option agreement with Velo to acquire the rights to digoxin immune fab, a polyclonal antibody in clinical development for the treatment of severe preeclampsia in pregnant women. The company sells Feraheme to authorized wholesalers and specialty distributors. It has a license agreement with Palatin Technologies, Inc. to research, develop, and commercialize Rekynda, an investigational product designed to be an on-demand treatment for hypoactive sexual desire disorder in pre-menopausal women, as well as with Endoceutics, Inc. to develop and commercialize pharmaceutical products with dehydroepiandrosterone; and development and license agreement with Antares Pharma, Inc. to develop, use, sell, and offer for sale and import and export the Makena auto-injector. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

Kamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. It operates through two segments, Proprietary Products and Distribution. The companyÂ’s respiratory products include Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital AAT deficiency (AATD); Bramitob to manage chronic pulmonary infection; and FOSTER for the treatment of asthma. Its immunoglobulin products comprise KamRAB for prophylaxis against rabies disease; KamRho (D) IM to treat prophylaxis of hemolytic disease of newborns; KamRho(D)IV for immune thermobocytopunic purpura; snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus; IVIG 5% for the treatment of various immunodeficiency-related conditions; Varitect, a varicella zoster immunoglobulin; Zutectra, a hepatitis B immunoglobulin; Hepatect CP, a hepatitis B immunoglobulin; and Megalotect, a CMV immunoglobulin. The company also provides critical care products, such as Heparin sodium injection to treat thrombo-embolic disorders; and Albumin for maintenance of blood plasma. In addition, it offers other products, including Heparin Lock Flush to maintain patency of indwelling IV catheter; Kamacaine 0.5% used as anesthesia for surgery, diagnostic, therapeutic, and obstetrical procedures, as well as spinal anesthesia for surgery; Human Transferrin for diagnostic assays and cell cultures; and coagulation factors comprising Factor VIII and Factor IX. Further, the company develops various inhaled formulations of AAT to treat AATD, cystic fibrosis, bronchiectasis, type-1 diabetes, graft-versus-host diseases, and transplantations. Kamada Ltd. has strategic partnerships with Baxter International Inc.; Chiesi Farmaceutici; PARI GmbH; and Kedrion S.p.A. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. was founded in 1990 and is headquartered in Ness Ziona, Israel.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.